ライフサイエンスコーパス: myeloproliferative disorder

1 nous leukemia, myelodysplastic syndrome, and myeloproliferative disorders).

2 lomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder.

3 s noted in more than half of patients with a myeloproliferative disorder.

4 smic tyrosine kinase JAK2 in patients with a myeloproliferative disorder.

5 atory features that were characteristic of a myeloproliferative disorder.

6 aling can translate into the occurrence of a myeloproliferative disorder.

7 osinophilic syndrome (HES) and an underlying myeloproliferative disorder.

8 a retroviral transduction assay results in a myeloproliferative disorder.

9 nsion of repopulating cells accompanied by a myeloproliferative disorder.

10 ype 1 in patients with an atypical stem cell myeloproliferative disorder.

11 Chronic myelogenous leukemia is a myeloproliferative disorder.

12 ematopoiesis that can best be described as a myeloproliferative disorder.

13 sis of hematological malignancies or chronic myeloproliferative disorders.

14 he adjacent kinase domain (JH1) resulting in myeloproliferative disorders.

15 potentially vascular events) associated with myeloproliferative disorders.

16 n in Jak2 is associated with a proportion of myeloproliferative disorders.

17 w discusses how this process is unfolding in myeloproliferative disorders.

18 ling in the Philadelphia chromosome negative myeloproliferative disorders.

19 derstanding of the molecular pathogenesis of myeloproliferative disorders.

20 2 have been identified in JAK2V617F negative myeloproliferative disorders.

21 veloping a specifically targeted therapy for myeloproliferative disorders.

22 se 2, found in the majority of patients with myeloproliferative disorders.

23 use for diseases such as leukemias and other myeloproliferative disorders.

24 eatment of JAK2(V617F)-positive PV and other myeloproliferative disorders.

25 on in Jak2 has recently been associated with myeloproliferative disorders.

26 derstanding of the molecular pathogenesis of myeloproliferative disorders.

27 V617F, and the pathogenesis of JAK2-negative myeloproliferative disorders.

28 patients with myelodysplastic syndromes and myeloproliferative disorders.

29 ne investigated as a potential treatment for myeloproliferative disorders.

30 diagnosis, classification, and treatment of myeloproliferative disorders.

31 has recently been shown for the JAK2 gene in myeloproliferative disorders.

32 onocytic hyperplasia and progressed to fatal myeloproliferative disorders.

33 myelopoiesis under normal conditions and in myeloproliferative disorders.

34 odysplastic characteristics with features of myeloproliferative disorders.

35 ell as methylation of these genes in several myeloproliferative disorders.

36 gulated protein tyrosine kinases involved in myeloproliferative disorders.

37 signaling pathway may contribute to various myeloproliferative disorders.

38 ntial use in the treatment of thrombotic and myeloproliferative disorders.

39 the BM niche and affects the development of myeloproliferative disorders.

40 c transplantation and worst in patients with myeloproliferative disorders.

41 mimics for the treatment of inflammatory and myeloproliferative disorders.

42 es to treat the energy imbalance observed in myeloproliferative disorders.

43 sions observed in patients with leukemia and myeloproliferative disorders.

44 ausal role of an activating JAK2 mutation in myeloproliferative disorders.

45 RAPL expression is widely abrogated in human myeloproliferative disorders.

46 cilitates progression to the blast phases of myeloproliferative disorders.

47 cell disease, myelodysplastic syndromes, and myeloproliferative disorders.

48 venous shunts (23%), lung disease (16%), and myeloproliferative disorders (8%).

49 Primary polycythaemia is a myeloproliferative disorder, a non-malignant stem-cell d

50 mia (CML), the phenotype closely resembles a myeloproliferative disorder affecting the megakaryocytic

51 22 of 26 patients with clinical evidence of myeloproliferative disorder and 1 patient with clinicall

52 n syndrome (trisomy 21)-associated transient myeloproliferative disorder and acute megakaryoblastic l

53 iscovered that nearly all cases of transient myeloproliferative disorder and acute megakaryocytic leu

54 eness of the role of trisomy 21 in transient myeloproliferative disorder and acute megakaryocytic leu

55 ts supports redefinition of the disease as a myeloproliferative disorder and provides opportunities t

56 12D), trap Ras in the active state and cause myeloproliferative disorder and T cell leukemia (T-ALL)

57 rmed stem cells that give rise to a distinct myeloproliferative disorder and T-lymphoblastic leukemia

58 itors, including the Down syndrome-transient myeloproliferative disorder and the thrombocytopenia abs

59 findings suggest new avenues for therapy of myeloproliferative disorders and atherosclerosis.

60 ents with polycythemia vera or other chronic myeloproliferative disorders and control subjects.

61 roven beneficial effects in the treatment of myeloproliferative disorders and inflammatory conditions

62 Myeloproliferative disorders and myelodysplastic syndrom

63 antineoplastic agent commonly used to treat myeloproliferative disorders and other nonneoplastic con

64 resent in patients with myelofibrosis due to myeloproliferative disorders and that these features are

65 mice: it increases both the severity of the myeloproliferative disorders and the self-renewal proper

66 ce, displayed leukocytosis, a transplantable myeloproliferative disorder, and a dramatic expansion of

67 , acute megakaryoblastic leukemia, transient myeloproliferative disorder, and a group of related cong

68 pulation, reduced leukocytosis, reversed the myeloproliferative disorder, and accelerated atheroscler

69 ents with AML, DS infants with the transient myeloproliferative disorder, and Epstein-Barr Virus (EBV

70 er, a preleukemic condition termed transient myeloproliferative disorder, and increased incidence of

71 matory demyelinating polyradiculoneuropathy, myeloproliferative disorder, and monoclonal gammopathy o

72 of disorders including inherited cytopenias, myeloproliferative disorders, and erythromegakaryocytic

73 tribute to the pathogenesis of JAK2-negative myeloproliferative disorders, and led to the discovery o

74 617F)) in essential thrombocythemia, related myeloproliferative disorders, and the impact on clinical

75 n to alter the diagnostic criteria for these myeloproliferative disorders, and these changes are revi

76 The classic BCR-ABL negative myeloproliferative disorders are at a crossroads of rapi

77 Patients with myeloproliferative disorders are at a high risk of devel

78 The myeloproliferative disorders are clonal disorders with f

79 Myelodysplasia and the myeloproliferative disorders are clonal hematopoietic st

80 this study, we have used the murine CML-like myeloproliferative disorder as a platform to characteriz

81 myeloid leukemia (CML) or polycythemia vera, myeloproliferative disorders associated with the BCR-ABL

82 leiotropic phenotype of JAK2V617F-associated myeloproliferative disorders been delineated.

83 Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that

84 Cre, LSL-Nras(G12D) mice develop an indolent myeloproliferative disorder but ultimately die of a dive

85 ated by thrombopoietin (THPO), is mutated in myeloproliferative disorders but rarely in AML.

86 D mutant proteins are sufficient to induce a myeloproliferative disorder, but are insufficient to rec

87 LSL-Kras(G12D) mice, which die of aggressive myeloproliferative disorder by 4 months of age.

88 oduct will contribute to progression of this myeloproliferative disorder by constitutive activation o

89 nt progress in the molecular pathogenesis of myeloproliferative disorders calls for a paradigm shift

90 In patients with myeloproliferative disorders CD177 mRNA overexpression i

91 romyelomonocyte leukemic cell line) and MPD (myeloproliferative disorder cell line), following differ

92 ogene causes chronic myelogenous leukemia, a myeloproliferative disorder characterized by clonal expa

93 causes chronic myelogenous leukemia (CML), a myeloproliferative disorder characterized by clonal expa

94 ICSBP-deficient mice develop a myeloproliferative disorder characterized by cytokine hy

95 anded MDR1-transduced stem cells developed a myeloproliferative disorder characterized by high periph

96 Langerhans cell histiocytosis (LCH) is a myeloproliferative disorder characterized by lesions com

97 ile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by malignant t

98 etic defects, aged Runx3 KO mice developed a myeloproliferative disorder characterized by myeloid-dom

99 I-expressing hematopoietic cells developed a myeloproliferative disorder characterized by overproduct

100 pathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent

101 Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterized by the genetic

102 myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based

103 Because the therapies for myeloproliferative disorders differ, our data have major

104 drome (DS) infants are born with a transient myeloproliferative disorder (DS-TMD) that spontaneously

105 The majority of the BCR-ABL-negative myeloproliferative disorders express the mutant JAK2, JA

106 n mouse haematopoietic stem cells leads to a myeloproliferative disorder, followed by acute T-lymphob

107 Human myeloproliferative disorders form a range of clonal haem

108 n blood counts relative to mutation-negative myeloproliferative disorders; future preclinical researc

109 f Janus kinase 2 and associated mutations in myeloproliferative disorders (> 95% in polycythemia vera

110 sis of essential thrombocythemia as a clonal myeloproliferative disorder has been clearly established

111 the classic Philadelphia-chromosome negative myeloproliferative disorders has made it a much anticipa

112 ysiology of Philadelphia-chromosome negative myeloproliferative disorders has significantly advanced

113 ing acute megakaryocytic leukemia, transient myeloproliferative disorder, Hirschsprung disease, duode

114 I571-treated mice were cured of the CML-like myeloproliferative disorder, however, and STI571-treated

115 ripheral blood and bone marrow, suggesting a myeloproliferative disorder; however, granulocyte precur

116 ated kinase 2 (JAK2) mutations are common in myeloproliferative disorders; however, although they are

117 was first described in 1879, classified as a myeloproliferative disorder in 1951, and characterized a

118 CSF3R T618I, is sufficient to drive a lethal myeloproliferative disorder in a murine bone marrow tran

119 novel useful tool for establishing a clonal myeloproliferative disorder in JAK2 and MPL wt patients

120 Bone marrow chimeras confirmed that the myeloproliferative disorder in lal(-/-) mice was primari

121 etroviral transduction efficiently induces a myeloproliferative disorder in mice resembling human CML

122 FLT3-ITDs induced an oligoclonal myeloproliferative disorder in mice, characterized by sp

123 le to generate specifically kRASG12D-induced myeloproliferative disorder in recipient fish.

124 ur results can explain the absence of clonal myeloproliferative disorders in mice (lifetime, 2 years)

125 has recently been described in a spectrum of myeloproliferative disorders including myelofibrosis wit

126 oid progenitors is a major characteristic of myeloproliferative disorders, including chronic myeloid

127 may contribute to phenotypic diversity among myeloproliferative disorders, including in the presence

128 Using three different mouse models of myeloproliferative disorders, including mice with defect

129 tyrosine kinase (V617F) and bcr/abl-negative myeloproliferative disorders, including MMM.

130 ities in these processes are associated with myeloproliferative disorders, including thrombocytopenia

131 Mll5 did not alter the phenotype of a fatal myeloproliferative disorder induced by oncogenic Kras in

132 brafish embryos, including rhabdomyosarcoma, myeloproliferative disorder, intestinal hyperplasia, and

133 Investigational approaches to myeloproliferative disorders involve targeting the bone

134 A recently described atypical myeloproliferative disorder is invariably associated wit

135 A high metabolic rate in myeloproliferative disorders is a common complication of

136 A major cause of morbidity in myeloproliferative disorders is thrombosis, although the

137 f pathologists and clinical investigators in myeloproliferative disorders; it was subsequently presen

138 matologic malignancies, including leukemias, myeloproliferative disorders, lymphomas, and multiple my

139 Cdc42-deficient mice developed a fatal myeloproliferative disorder manifested by significant le

140 gulated mast cell growth associated with the myeloproliferative disorder, mastocytosis.

141 obstruction to hepatic venous outflow, with myeloproliferative disorder (MPD) accounting for up to 4

142 nsformed with BCR-ABL(P210) initiated both a myeloproliferative disorder (MPD) and B-lymphoid leukemi

143 ature T-cell lymphomas (CD4(+), CD8(+)) or a myeloproliferative disorder (MPD) at increased rates and

144 etroviral transduction efficiently induces a myeloproliferative disorder (MPD) in mice resembling hum

145 etroviral transduction efficiently induces a myeloproliferative disorder (MPD) in mice resembling hum

146 BCR-ABL efficiently induces a myeloproliferative disorder (MPD) in mice, but progressi

147 mpared the effects of inhibitors of MEK in a myeloproliferative disorder (MPD) initiated by inactivat

148 PL) mutations, MPLW515L/K, were described in myeloproliferative disorder (MPD) patients.

149 ation of JunB in postnatal mice results in a myeloproliferative disorder (MPD) resembling early human

150 emia/lymphoma syndrome usually presents as a myeloproliferative disorder (MPD) that evolves to acute

151 mphoma syndrome usually presents itself as a myeloproliferative disorder (MPD) that evolves to acute

152 /-) hematopoietic stem cells develop a fatal myeloproliferative disorder (MPD) that models JMML.

153 zyme 12/15-lipoxygenase (12/15-LO) develop a myeloproliferative disorder (MPD) that progresses to tra

154 Chronic myelogenous leukemia is a myeloproliferative disorder (MPD) that, over time, progr

155 Myeloproliferative disorder (MPD) was observed in murine

156 murine models ICSBP deficiency results in a myeloproliferative disorder (MPD) with increased mature

157 terozygous Nf1 mutant mice develop a similar myeloproliferative disorder (MPD), and adoptive transfer

158 BCS patients are found to have an underlying myeloproliferative disorder (MPD), antiplatelet therapy

159 myeloid and T-lymphoid lineages and develop myeloproliferative disorder (MPD).

160 tic leukemia, and Nf1 mutant mice model this myeloproliferative disorder (MPD).

161 e myelomonocytic leukemia (JMML), which is a myeloproliferative disorder (MPD).

162 The chronic myeloproliferative disorders (MPD) are clonal hematopoie

163 Myeloproliferative disorders (MPD) are stem cell-derived

164 lso is associated with a risk for developing myeloproliferative disorders (MPD), including juvenile m

165 myelodysplastic syndromes (MDS), overlap MDS/myeloproliferative disorders (MPD), MPD, and acute myelo

166 lofibrosis (PMF) as pathogenetically related myeloproliferative disorders (MPD).

167 elofibrosis, and less frequently in atypical myeloproliferative disorders (MPD).

168 on mutation in the majority of patients with myeloproliferative disorders (MPD).

169 an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro stu

170 chromosomal abnormality associated with the myeloproliferative disorders (MPDs) and is also found in

171 is present in the majority of patients with myeloproliferative disorders (MPDs) and is implicated in

172 Because myeloproliferative disorders (MPDs) are a frequent cause

173 Myeloproliferative disorders (MPDs) are characterized by

174 Myeloproliferative disorders (MPDs) are characterized by

175 Myeloproliferative disorders (MPDs) are clonal malignanc

176 Myeloproliferative disorders (MPDs) are thought to be cl

177 ffective therapeutic agent for patients with myeloproliferative disorders (MPDs) or sickle cell disea

178 alence of this mutation in either "atypical" myeloproliferative disorders (MPDs) or the myelodysplast

179 Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, e

180 heral blood CD34(+) cells of 2 patients with myeloproliferative disorders (MPDs) who acquired the JAK

181 Eosinophilia is common in myeloproliferative disorders (MPDs) with abnormalities o

182 Myeloproliferative disorders (MPDs), either transient or

183 7F) mutation was found in most patients with myeloproliferative disorders (MPDs), including polycythe

184 ation (JAK2 V617F) is present in the chronic myeloproliferative disorders (MPDs), polycythemia vera (

185 Patients with myeloproliferative disorders (MPDs), such as essential t

186 2-V617F, a critical JAK2 mutation in various myeloproliferative disorders (MPDs).

187 aditional diagnostic classification of these myeloproliferative disorders (MPDs).

188 ine kinase was recently described in chronic myeloproliferative disorders (MPDs).

189 ly decreased on platelets from patients with myeloproliferative disorders (MPDs).

190 tients with Philadelphia chromosome-negative myeloproliferative disorders (MPDs).

191 eloped a clinical picture closely resembling myeloproliferative disorders/neoplasms (MPNs), including

192 The chronic myelogenous leukemia (CML)-like myeloproliferative disorder observed in the BCR/ABL muri

193 Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder of childhood caused by mutat

194 enile myelomonocytic leukemia, an aggressive myeloproliferative disorder of childhood.

195 kemia is an aggressive and frequently lethal myeloproliferative disorder of childhood.

196 lastic disorder reminiscent of the transient myeloproliferative disorder of Down syndrome.

197 me present with lymphoblastic lymphoma and a myeloproliferative disorder, often accompanied by pronou

198 We present here seven patients with myeloproliferative disorders or myelodysplastic syndrome

199 on and differentiation can lead to leukemia, myeloproliferative disorders, or marrow failure; however

200 ocus on the pathophysiology of thrombosis in myeloproliferative disorders, particularly in terms of t

201 chromosome 20 is a recurrent abnormality in myeloproliferative disorders, particularly polycythemia

202 athogenesis, including a contribution to the myeloproliferative disorder phenotype by a gain-of-funct

203 Familial or childhood occurrence of the myeloproliferative disorder polycythemia vera are also d

204 occurs in the majority of patients with the myeloproliferative disorders polycythemia vera, essentia

205 The myeloproliferative disorders polycythemia vera, essentia

206 molecular lesion in eosinophilia-associated myeloproliferative disorders, predicting a favorable res

207 Current therapy for myeloproliferative disorders remains largely based on pr

208 lonal evolution from a preleukemic transient myeloproliferative disorder requiring both a trisomy 21

209 topoietic stem cell transplantation (AHSCT), Myeloproliferative Disorder Research Consortium 101 tria

210 The Myeloproliferative Disorders Research Consortium (MPD-RC

211 Myeloproliferative Disorders Research Consortium 112 was

212 mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that

213 chromosomal aberrations and develop a fatal myeloproliferative disorder resembling chronic myelomono

214 mice known to develop, after long latency, a myeloproliferative disorder resembling human CML.

215 ronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplasti

216 onic myelomonocytic leukemia/myelodysplastic/myeloproliferative disorder similar to that seen in huma

217 Four out of 25 primary mice succumbed to myeloproliferative disorders, some of which progressed t

218 a sizeable proportion of patients with other myeloproliferative disorders such as essential thrombocy

219 ations in chronic myeloid leukemia and other myeloproliferative disorders suggested the possibility t

220 poietic cells into irradiated mice induces a myeloproliferative disorder that did not respond to L-74

221 ytogenetic abnormality seen in a nonspecific myeloproliferative disorder that is associated with T-ce

222 Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder that predominantly affects i

223 ous miRNA, miR-125b, caused a dose-dependent myeloproliferative disorder that progressed to a lethal

224 id differentiation, and the development of a myeloproliferative disorder that progresses to acute mye

225 on of HoxA10 in murine bone marrow induces a myeloproliferative disorder that progresses to AML over

226 nd that expression of Bcr-Abl/p210 induced a myeloproliferative disorder that resembled the chronic p

227 CML is a myeloproliferative disorder that results from dysregulat

228 activity in eosinophilia-associated chronic myeloproliferative disorders that are characterized by a

229 a (ET) and polycythemia vera (PV) are clonal myeloproliferative disorders that are often difficult to

230 The molecular mechanisms in myeloproliferative disorders that prevent apoptosis indu

231 the diagnosis of an underlying Ph1-negative myeloproliferative disorder, that is, polycythemia vera

232 ribed in polycythemia vera and other BCR-ABL myeloproliferative disorders; the particular discovery h

233 derstanding of the molecular pathogenesis of myeloproliferative disorders, though many questions rema

234 2 related hematopoietic diseases: transient myeloproliferative disorder (TMD) and acute megakaryobla

235 al erythropoietic porphyria (CEP), transient myeloproliferative disorder (TMD) and acute megarakaryob

236 the pathogenesis of Down syndrome-transient myeloproliferative disorder (TMD) and Down syndrome-acut

237 th Down syndrome (DS) present with transient myeloproliferative disorder (TMD) at or shortly after bi

238 Both DS-AMKL and the related transient myeloproliferative disorder (TMD) have GATA1 mutations a

239 ) and in nearly every patient with transient myeloproliferative disorder (TMD), a "preleukemia" that

240 ividuals with DS who are born with transient myeloproliferative disorder (TMD), a clonal preleukemia,

241 a (AMKL); DS newborns present with transient myeloproliferative disorder (TMD), a preleukemic form of

242 are diagnosed with self-regressing transient myeloproliferative disorder (TMD), and 20% to 30% of tho

243 en reported in Down syndrome (DS), transient myeloproliferative disorder (TMD), and acute megakaryobl

244 Transient myeloproliferative disorder (TMD), restricted to newborn

245 in whom it is often preceded by a transient myeloproliferative disorder (TMD).

246 4%-5% of newborns with DS develop transient myeloproliferative disorder (TMD).

247 ndividuals with Down syndrome with transient myeloproliferative disorder (TMD, also called transient

248 karyocytic proliferation disorder (transient myeloproliferative disorder [TMD]).

249 scriptional regulatory genes, whereas in the myeloproliferative disorders tyrosine kinases are freque

250 617F in the Philadelphia-chromosome negative myeloproliferative disorders, unlike bcr/abl tyrosine ki

251 atients were further subdivided into primary myeloproliferative disorders versus secondary thrombocyt

252 It is of note, however, that no case of myeloproliferative disorder was observed.

253 se levels are elevated in some patients with myeloproliferative disorders, we examined their utility

254 ral blood mononuclear cells of patients with myeloproliferative disorders, we isolated numerous genes

255 To study clonal evolution in myeloproliferative disorders, we used stochastic models

256 h regulation of ROS levels and the resulting myeloproliferative disorder when dysregulated.

257 sent a novel in vivo model for a Myc-induced myeloproliferative disorder which can be controlled.

258 t mice, as they age, spontaneously develop a myeloproliferative disorder, which progresses from myelo

259 Patients with myeloproliferative disorders who were treated with hydro

260 ogenous murine locus rapidly induces a fatal myeloproliferative disorder with 100% penetrance charact

261 Somatic inactivation of Nf1 induces a myeloproliferative disorder with 100% penetrance that is

262 Sca(+/AE) mice develop a spontaneous myeloproliferative disorder with a latency of 6 months a

263 ion studies, HoxA10 overexpression induces a myeloproliferative disorder with accumulation of mature

264 hrocytosis (familial polycythemia) is a rare myeloproliferative disorder with an autosomal dominant m

265 First, a myeloproliferative disorder with features characteristic

266 was efficacious in treatment of progressive myeloproliferative disorder with organomegaly.

267 -formatted siRNA against SHIP1 resulted in a myeloproliferative disorder, with striking similarities

268 studies are needed to elucidate the cause of myeloproliferative disorders without known disease allel